SEC Form 4
NovaBridge Biosciences (NBP) insider trading
In the 12 months to Oct 26, 2026, 2 NBP insiders reported open-market sales of $31.8K across 5 filings; one officer (see filing) bought $577.3K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $31.8K
- 5 filings · 2 insiders
- Open-market purchases
- $577.3K
- 1 filing · Mark Arnold Hagler, Officer (see filing)
Who traded NBP, and when
- Purchase
- Sale
NBP daily close from Oct 30, 2025 to Oct 26, 2026, between $1.22 and $4.95, last $1.22. 5 sale and 1 purchase filings by 3 insiders, marked at their filing dates. Mark Arnold Hagler, Officer (see filing): bought $577.3K across 1 filing, first filed Apr 28, 2026, last Apr 28, 2026. Cong Claire Xu, SVP, Clinical Development → EVP, Clinical Development: sold $20.4K across 3 filings, first filed Jun 2, 2026, last Sep 1, 2026. Phillip Andrew Dennis, Chief Medical Officer: sold $11.4K across 2 filings, first filed Jun 22, 2026, last Sep 21, 2026.
Largest mark · tap a row for others
Mark Arnold Hagler · Officer (see filing)
Purchase $577,300
230,000 shares
Filed Apr 28, 2026 · traded Apr 24
Close on filing date $2.39
Mark Arnold Hagler · Officer (see filing)
Officer (see filing)
$577.3K boughtCong Claire Xu · SVP, Clinical Development → EVP, Clinical Development
SVP, Clinical Development → EVP, Clinical Development
$20.4K soldPhillip Andrew Dennis · Chief Medical Officer
Chief Medical Officer
$11.4K soldOpen-market trades
6 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Mark Arnold Hagler | Officer (see filing) | — | $577.3K | 1 | — | |
| Cong Claire Xu | SVP, Clinical Development → EVP, Clinical Development | $20.4K | — | 3 | — | |
| Phillip Andrew Dennis | Chief Medical Officer | $11.4K | — | 2 | — |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | Phillip Andrew Dennis Chief Medical Officer | Sale | 8,209 ordinary shares | $5.8K | 173,427 | |
traded | Cong Claire Xu EVP, Clinical Development | Sale | 3,282 ordinary shares | $2.6K | 304,201 | |
traded | Cong Claire Xu SVP, Clinical Development | Sale | 4,485 ordinary shares | $4.0K | 298,101 | |
traded | Phillip Andrew Dennis Chief Medical Officer | Sale | 8,494 ordinary shares | $5.6K | 157,941 | |
traded | Cong Claire Xu SVP, Clinical Development | Sale | 3,494 ordinary shares | $13.8K | 290,154 | |
traded | Mark Arnold Hagler Officer (see filing) | Purchase | 230,000 ordinary shares | $577.3K | 230,000 |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=NBP&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NBP"
],
"issuer_cik": "0001778016",
"owner_cik": "0002089237",
"accession_number": "0002089237-26-000008",
"form_type": "4",
"filing_date": "2026-09-21",
"period_of_report": "2026-09-17",
"issuer_name": "NovaBridge Biosciences",
"issuer_trading_symbol": "NBP",
"owner_name": "Dennis Phillip Andrew",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Medical Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 8209,
"transaction_price_per_share": 0.71,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 173427,
"transaction_value": 5828.389999999999,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer."
},
{
"id": "F5",
"description": "Reported securities are represented by 3,569 ADSs."
},
{
"id": "F6",
"description": "Reported sales price represents the converted sales price of the ADSs of $1.6247."
},
{
"id": "F7",
"description": "Reported securities are represented by 75,403 ADSs."
}
]
},
{
"tickers": [
"NBP"
],
"issuer_cik": "0001778016",
"owner_cik": "0002114309",
"accession_number": "0002114309-26-000007",
"form_type": "4",
"filing_date": "2026-09-01",
"period_of_report": "2026-08-30",
"issuer_name": "NovaBridge Biosciences",
"issuer_trading_symbol": "NBP",
"owner_name": "Xu Cong Claire",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, Clinical Development",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-31",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 3282,
"transaction_price_per_share": 0.79,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 304201,
"transaction_value": 2592.78,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The Ordinary Shares may be represented by American Depositary Shares (\"ADS\"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer."
},
{
"id": "F5",
"description": "Reported securities are represented by 1,427 ADSs."
},
{
"id": "F6",
"description": "Reported sales price represents the converted sales price of the ADSs of $1.8186."
},
{
"id": "F7",
"description": "Reported securities are represented by 132,261 ADSs."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 11 records
- Option exercises9 records
- Tax withholding (sold to cover)2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has NovaBridge Biosciences' CEO sold stock?
No. Srishti Gupta (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is NBP’s insider data?
These are NBP Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track NBP insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NBP every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.